Evaluation of a protease activation mutant of Sendai virus as a potent live vaccine.
A protease activation mutant of Sendai virus, TR-5, was investigated as a candidate for a live vaccine. Vaccination with TR-5 which had been activated by chymotrypsin beforehand (active TR-5) elicited protective immunity against otherwise lethal challenge infection with wild-type Sendai virus in DBA/2, C3H and ICR strains of mice. Less of the active TR-5 was required to confer protection on mice compared with an ordinary ether-inactivated Sendai virus vaccine (split vaccine). The protective immunity elicited by TR-5 lasted longer and the booster effect was more prominent compared to the split vaccine. No seroconversion was observed with contact mice when housed in a cage with mice vaccinated with the active TR-5. The overall results show that the active TR-5 is an effective and safe live vaccine of Sendai virus in mice.
Maru
M
M
Shionogi Research Laboratories, Shionogi and Co., Ltd., Osaka, Japan.
Haraguchi
M
M
Sato
K
K
Hotta
H
H
Homma
M
M
D000280:Administration, Inhalation; D000336:Aerosols; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D005260:Female; D006385:Hemagglutination Inhibition Tests; D007117:Immunization, Secondary / Q000662:veterinary; D051379:Mice; D008809:Mice, Inbred C3H; D008811:Mice, Inbred DBA; D008813:Mice, Inbred ICR; D008815:Mice, Inbred Strains; D009154:Mutation; D010222:Parainfluenza Virus 1, Human / Q000235:genetics / Q000276:immunology*; D018184:Paramyxoviridae Infections / Q000517:prevention & control / Q000662:veterinary*; D012376:Rodent Diseases / Q000517:prevention & control*; D014611:Vaccination / Q000662:veterinary; D014613:Vaccines, Attenuated / Q000008:administration & dosage; D014765:Viral Vaccines / Q000008:administration & dosage
D000336:Aerosols; D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines